Total Payments
$26,255
2024 Payments
$1,017
Companies
36
Transactions
523
Medicare Patients
2,876
Medicare Billing
$398,376
Payment Breakdown by Category
Food & Beverage$12,869 (49.0%)
Other$8,350 (31.8%)
Research$4,663 (17.8%)
Education$354.58 (1.4%)
Travel$18.45 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,869 | 488 | 49.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,350 | 9 | 31.8% |
| Unspecified | $4,663 | 4 | 17.8% |
| Education | $354.58 | 20 | 1.4% |
| Travel and Lodging | $18.45 | 2 | 0.1% |
Payments by Type
General
$21,592
519 transactions
Research
$4,663
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $10,274 | 64 | $0 (2024) |
| Neurocrine BioSciences, Inc. | $4,663 | 4 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,549 | 56 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,292 | 46 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $1,170 | 41 | $0 (2023) |
| Novo Nordisk Inc | $1,049 | 47 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $871.69 | 60 | $0 (2024) |
| Amgen Inc. | $650.06 | 18 | $0 (2024) |
| Lilly USA, LLC | $597.91 | 12 | $0 (2024) |
| Amarin Pharma Inc. | $538.70 | 36 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,017 | 34 | Novo Nordisk Inc ($372.99) |
| 2023 | $1,669 | 72 | Boehringer Ingelheim Pharmaceuticals, Inc. ($320.18) |
| 2022 | $3,140 | 74 | Neurocrine BioSciences, Inc. ($1,513) |
| 2021 | $6,392 | 100 | AstraZeneca Pharmaceuticals LP ($3,507) |
| 2020 | $7,866 | 59 | AstraZeneca Pharmaceuticals LP ($4,854) |
| 2019 | $2,503 | 66 | AstraZeneca Pharmaceuticals LP ($805.32) |
| 2018 | $2,166 | 65 | AstraZeneca Pharmaceuticals LP ($743.48) |
| 2017 | $1,501 | 53 | Novartis Pharmaceuticals Corporation ($207.51) |
All Payment Transactions
523 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $32.42 | General |
| Category: Cardiovascular | ||||||
| 11/21/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $8.24 | General |
| Category: Diabetes | ||||||
| 11/19/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $124.99 | General |
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $22.28 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/07/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $5.45 | General |
| 11/05/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $22.33 | General |
| Category: Cardiology | ||||||
| 10/30/2024 | BIOTRONIK INC. | — | Food and Beverage | In-kind items and services | $30.52 | General |
| 10/24/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/17/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/16/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $37.37 | General |
| Category: Cardiovascular | ||||||
| 10/08/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $21.83 | General |
| Category: Diabetes | ||||||
| 09/25/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $30.05 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/25/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $19.52 | General |
| Category: Diabetes | ||||||
| 07/30/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/22/2024 | Bausch Health US, LLC | APLENZIN (Drug) | Food and Beverage | In-kind items and services | $16.65 | General |
| Category: Neurology | ||||||
| 07/16/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.57 | General |
| Category: Diabetes | ||||||
| 07/02/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $26.04 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/13/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $123.90 | General |
| Category: Obesity | ||||||
| 06/11/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $29.01 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/08/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $97.54 | General |
| Category: Diabetes | ||||||
| 05/07/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/02/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $34.73 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/17/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $28.82 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $30.41 | General |
| Category: DIABETES | ||||||
| 04/03/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.12 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | Neurocrine Biosciences, Inc. | $3,150 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | Neurocrine BioSciences, Inc. | $1,513 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 878 | 1,202 | $255,596 | $117,756 |
| 2022 | 12 | 671 | 973 | $181,493 | $87,813 |
| 2021 | 14 | 657 | 998 | $190,003 | $99,923 |
| 2020 | 14 | 670 | 1,074 | $194,755 | $92,884 |
Total Patients
2,876
Total Services
4,247
Medicare Billing
$398,376
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 197 | 455 | $115,555 | $49,019 | 42.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 121 | 123 | $47,365 | $24,399 | 51.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 82 | 82 | $31,745 | $14,615 | 46.0% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 39 | 39 | $15,740 | $9,241 | 58.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 36 | 41 | $12,495 | $6,562 | 52.5% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 15 | 17 | $6,729 | $4,491 | 66.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 40 | 45 | $8,805 | $3,305 | 37.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 174 | 216 | $9,685 | $2,764 | 28.5% |
| 90682 | Influenza vaccine, quadrivalent derived from recombinant dna | Office | 2023 | 18 | 18 | $2,061 | $1,295 | 62.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 20 | 21 | $1,465 | $762.09 | 52.0% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 28 | 28 | $1,640 | $643.72 | 39.3% |
| 93246 | Heart rhythm recording of continous external ekg over 8-15 days | Office | 2023 | 28 | 28 | $1,600 | $351.22 | 22.0% |
| 81002 | Urinalysis, manual test | Office | 2023 | 80 | 89 | $710.50 | $309.39 | 43.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 161 | 382 | $89,830 | $40,915 | 45.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 72 | 77 | $27,836 | $15,526 | 55.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 43 | 50 | $15,400 | $8,063 | 52.4% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2022 | 30 | 31 | $12,555 | $7,416 | 59.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 37 | 37 | $13,895 | $6,538 | 47.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 42 | 47 | $6,845 | $3,685 | 53.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 140 | 186 | $8,370 | $2,424 | 29.0% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 20 | 21 | $1,650 | $1,464 | 88.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 21 | 22 | $1,100 | $795.32 | 72.3% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2022 | 16 | 19 | $1,685 | $432.74 | 25.7% |
| 81002 | Urinalysis, manual test | Office | 2022 | 73 | 82 | $652.00 | $283.83 | 43.5% |
| 93246 | Heart rhythm recording of continous external ekg over 8-15 days | Office | 2022 | 16 | 19 | $1,675 | $270.21 | 16.1% |
About Dr. Richard Levy, MD
Dr. Richard Levy, MD is a Cardiovascular Disease healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356421408.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Levy, MD has received a total of $26,255 in payments from pharmaceutical and medical device companies, with $1,017 received in 2024. These payments were reported across 523 transactions from 36 companies. The most common payment nature is "Food and Beverage" ($12,869).
As a Medicare-enrolled provider, Levy has provided services to 2,876 Medicare beneficiaries, totaling 4,247 services with total Medicare billing of $398,376. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location San Francisco, CA
- Active Since 10/16/2006
- Last Updated 02/20/2020
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1356421408
Products in Payments
- FARXIGA (Drug) $9,448
- JARDIANCE (Drug) $1,353
- ENTRESTO (Drug) $1,247
- ELIQUIS (Drug) $855.59
- MULTAQ (Drug) $688.25
- XARELTO (Drug) $553.08
- Vascepa (Drug) $538.70
- Livalo (Drug) $482.05
- Repatha (Biological) $460.79
- TRULICITY (Drug) $355.83
- Ozempic (Drug) $354.50
- Nuedexta (Drug) $342.65
- Kerendia (Drug) $284.04
- Wegovy (Drug) $266.87
- TOUJEO (Drug) $243.73
- MOUNJARO (Drug) $230.37
- VERQUVO (Drug) $227.23
- BRILINTA (Drug) $187.35
- Corlanor (Drug) $181.93
- PRADAXA (Drug) $162.89
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in San Francisco
Dr. Philip Sager, Md, MD
Cardiovascular Disease — Payments: $851,687
Cardiovascular Disease $851,687
Dr. Melvin Scheinman, M.d, M.D
Cardiovascular Disease — Payments: $315,387
Cardiovascular Disease $315,387
Dr. Henry Hsia, Md, MD
Cardiovascular Disease — Payments: $296,299
Cardiovascular Disease $296,299
Edward Gerstenfeld, Md, MD
Cardiovascular Disease — Payments: $198,638
Cardiovascular Disease $198,638
Dr. Lloyd Klein, Md, MD
Cardiovascular Disease — Payments: $176,194
Cardiovascular Disease $176,194
Robert Gillespie, M.d, M.D
Cardiovascular Disease — Payments: $116,323
Cardiovascular Disease $116,323